MetaCap

Curanex Pharmaceuticals (CURX) vs MetaVia (MTVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Curanex Pharmaceuticals is the larger company by market cap ($6.9 million vs $6.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CURX-7.54%MTVA-30.82%
+33%-0%-34%
Oct 7, 20261 yearNov 20, 2026
CURX-16.94%MTVA-28.37%
+19%-6%-31%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CURX versus MTVA key metrics
MetricCURXMTVA
Share price$4.41$1.01
Market cap$6.92M$6.81M
1-day change-0.67%-7.34%
EPS (TTM)$-8.78$-2.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-4.23M$-12.97M
52-week high$13.34$13.42
52-week low$3.58$0.966
Distance from 52-week high-66.94%-92.47%
Analyst consensus—none
Avg. price target upside—+1813.86%
Average volume17.83K113.44K
Shares outstanding1.57M6.74M
Employees68
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Curanex Pharmaceuticals

CURX stock →

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About MetaVia

MTVA stock →

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

CURX vs MTVA FAQ

Which is bigger, Curanex Pharmaceuticals or MetaVia?

Curanex Pharmaceuticals (CURX) is larger, with a market capitalization of $6.92M compared with $6.81M for MetaVia (MTVA).

Are Curanex Pharmaceuticals and MetaVia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons